| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1959-07-12 |
| Identifiers | MRN HR-ML051-SYN; SSN (made up) 000-51-2976 |
| Document date | 2026-09-14 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review on androgen deprivation with apalutamide, after radiotherapy to the prostate. [S]
Mr. Neruda returns three months after starting treatment, with a professional Spanish interpreter. He finished 20 fractions of radiotherapy to the prostate three weeks ago. During the last two weeks of treatment he had more frequent urination and looser stools, and both are settling: he now gets up once a night, and his bowels are once or twice a day, with no bleeding. The rash he had five weeks ago faded within two weeks on the cream and cetirizine, and he has stopped both. The hip pain has gone; he has not taken acetaminophen for three weeks. Hot flashes come four or five times a day. His weight is up 2 kg, and he tires in the afternoons but still walks daily and writes every morning. He has had no falls. His home blood pressure readings have been around 130/80 since the amlodipine increase. He asks whether the treatment is working. [S]
| Element | Detail |
|---|---|
| Radiotherapy | 55 Gy in 20 fractions, finished three weeks ago |
| Urinary and bowel | Nocturia once; stools once or twice a day, settling; no bleeding |
| Rash | Resolved; triamcinolone and cetirizine stopped |
| Pain | None; acetaminophen stopped three weeks ago |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon fatigue; weight up 2 kg |
| Endocrine | Positive | Hot flashes four or five times a day; no cold intolerance or constipation |
| Genitourinary | Positive | Nocturia once; no burning or blood |
| Gastrointestinal | Positive | Softer stools once or twice a day, settling; no bleeding |
| Integumentary | Negative | Rash gone |
| Musculoskeletal | Negative | No bone pain |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-04-06 to 2026-07-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-07-13 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 2026-06-01 to 2026-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, every twelve weeks | One injection every twelve weeks | Intramuscular route | 2026-06-22 | active | S |
| Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-15 | active | S |
| Denosumab 60 mg/mL prefilled syringe, 60 mg subcutaneously every six months, for high fracture risk on androgen deprivation | One injection every six months | Subcutaneous route | 2026-07-13 | active | S |
| Triamcinolone acetonide 0.1% cream, apply a thin layer to the rash twice daily for two weeks (not the face or groin) | Twice daily for two weeks | Topical route | 2026-08-10 to 2026-08-24 | completed | S |
| Cetirizine 10 mg oral tablet, one tablet daily for itch | One tablet daily | Oral route | 2026-08-10 to 2026-08-31 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-14 | Body height | 178 | cm | S |
| 2026-09-14 | Body weight | 94.2 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 29.7 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 72 | /min | S |
| 2026-09-14 | Respiratory rate | 14 | /min | S |
| 2026-09-14 | Body temperature | 36.6 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 0.18 | ng/mL | <=4 ng/mL | Normal | S |
| 2026-09-14 | Testosterone [Mass/volume] in Serum or Plasma | 14 | ng/dL | 264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivation | Low | S |
| 2026-09-14 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-09-14 | Leukocytes [#/volume] in Blood by Automated count | 5.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-09-14 | Platelets [#/volume] in Blood by Automated count | 231 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-09-14 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-14 | Glucose [Mass/volume] in Serum or Plasma | 102 | mg/dL | 70-99 mg/dL | High | S |
| 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.99 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-14 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 2026-09-14 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 40-129 U/L | Normal | S |
| 2026-09-14 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-09-14 | Thyrotropin [Units/volume] in Serum or Plasma | 5.4 | m[IU]/L | 0.45-4.5 mIU/L | High | S |
| 2026-09-14 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-09-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.1 | % | <=5.6% | High | S |
| 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-09-14 | International Prostate Symptom Score [IPSS] | 9 | {score} | S | ||
| 2026-09-14 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S |
Vital signs recorded on 2026-09-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 132/80 mm Hg; no ankle swelling |
| Neck | Thyroid not enlarged |
| Skin | No rash; mild darkening of the skin over the radiotherapy field |
| Neurological | Strength and sensation normal in both legs |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
| Maculopapular drug rash from apalutamide, grade 2 (about 20 percent of body surface, trunk and upper arms), eight weeks into treatment; no mucosal involvement, blistering, fever, eosinophilia or liver involvement; settled on topical steroid and an antihistamine without stopping apalutamide | resolved | confirmed | L27.0 | S — Synthetic intercurrent problem at an unscheduled visit; a known effect of apalutamide, not a historical claim. |
| Personal history of radiotherapy to the prostate (55 Gy in 20 fractions, finished three weeks before the three-month visit) | active | confirmed | Z92.3 | S — Synthetic: recorded after the course of radiotherapy finished. |
| Raised TSH (5.4 mIU/L) with a normal free T4 on apalutamide: subclinical, under observation | active | confirmed | R94.6 | S — Synthetic finding; raised TSH is a known effect of apalutamide. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA on androgen deprivation | Every 3 to 6 months | Completed today | 0.18 ng/mL at three months |
| Laboratory | Testosterone | Every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Completed today | 14 ng/dL, castrate |
| Laboratory | Blood count | Periodically in metastatic disease | Completed today | Hemoglobin 12.9 g/dL (mildly low); white cells and platelets normal |
| Laboratory | Chemistry with calcium and alkaline phosphatase | Periodically on denosumab and in metastatic disease | Completed today | Calcium 9.2 mg/dL; creatinine 0.99 mg/dL; alkaline phosphatase 96 U/L, normal |
| Laboratory | TSH and free T4 on apalutamide | About every four months | Completed today | TSH 5.4 mIU/L (raised); free T4 1.0 ng/dL (normal) |
| Laboratory | Hemoglobin A1c | Baseline and yearly on androgen deprivation; repeated at three months for prediabetes | Completed today | 6.1 percent, up from 5.9 |
| Laboratory | Lipid panel | Baseline and yearly on androgen deprivation | Up to date | Baseline at the first visit; statin decision at the annual wellness visit |
| Imaging | Bone density (DXA) | Every 1 to 2 years on androgen deprivation | Up to date | Baseline three months ago |
| Imaging | Restaging imaging | If PSA rises or symptoms appear | Not indicated | PSA 0.18 ng/mL and no symptoms |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 132/80 mm Hg on amlodipine 10 mg; home readings about 130/80 |
| Examination | Neurological check for spinal cord compression | Every visit with spinal metastases | Completed today | Normal |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Survey | Pain score | Every visit with symptomatic metastases | Completed today | 1 of 10 |
| Survey | Urinary symptoms (IPSS) | Every follow-up visit, particularly after radiotherapy | Completed today | IPSS 9, down from 17 |
| Survey | Bowel function after radiotherapy | Every visit after radiotherapy | Completed today | Softer stools once or twice a day, settling; no bleeding |
| Survey | Sexual function | Periodically on androgen deprivation | Completed today | Lower libido and erections, as expected; no treatment wanted now |
| Survey | Cognition | Periodically on androgen deprivation | Due | Mini-Cog at the annual wellness visit in three weeks |
| Medication safety | Rash on apalutamide | Every visit on androgen deprivation | Completed today | Resolved |
| Medication safety | Falls on apalutamide | Every visit on androgen deprivation | Completed today | No falls |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Completed today | Hot flashes four or five times a day; afternoon fatigue; no medicine wanted yet |
| Medication safety | Second leuprolide injection | Every twelve weeks | Completed today | Given today |
| Referral | Somatic tumor testing result | Once | Completed today | No homologous recombination repair alteration; microsatellite stable |
| Self-management | Physical activity, weight and calcium intake | Every visit | Completed today | Walking daily; resistance exercise twice a week; calcium from food |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026)
Follow-up: Annual wellness visit in three weeks. TSH and free T4 in about eight weeks. Medical oncology and the third leuprolide injection in twelve weeks, with PSA and testosterone. Denosumab again in four months. Next scheduled visit 2026-10-05: subsequent annual wellness visit. [S]